Abeona Therapeutics Inc (NASDAQ:ABEO) Director Sells $45,440.00 in Stock

Abeona Therapeutics Inc (NASDAQ:ABEO) Director Mark Alvino sold 8,000 shares of the stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $5.68, for a total value of $45,440.00. Following the completion of the transaction, the director now owns 92,435 shares of the company’s stock, valued at $525,030.80. The trade was a 7.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Abeona Therapeutics Stock Up 5.4%

Shares of NASDAQ ABEO opened at $6.10 on Monday. The stock has a market cap of $297.68 million, a P/E ratio of -2.27 and a beta of 1.68. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31. Abeona Therapeutics Inc has a 12-month low of $3.93 and a 12-month high of $7.32. The business’s fifty day simple moving average is $5.18 and its 200-day simple moving average is $5.55.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.11. As a group, equities analysts predict that Abeona Therapeutics Inc will post -1.16 EPS for the current fiscal year.

Institutional Trading of Abeona Therapeutics

Hedge funds have recently modified their holdings of the stock. Twinbeech Capital LP acquired a new stake in shares of Abeona Therapeutics in the fourth quarter valued at $58,000. Squarepoint Ops LLC acquired a new stake in shares of Abeona Therapeutics in the fourth quarter valued at $67,000. Cannon Global Investment Management LLC acquired a new stake in Abeona Therapeutics in the first quarter valued at $67,000. Oxford Asset Management LLP acquired a new stake in Abeona Therapeutics in the fourth quarter valued at $118,000. Finally, Balyasny Asset Management L.P. acquired a new stake in Abeona Therapeutics in the fourth quarter valued at $190,000. 80.56% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ABEO. Oppenheimer assumed coverage on Abeona Therapeutics in a research report on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 price objective for the company. Stifel Nicolaus decreased their target price on Abeona Therapeutics from $21.00 to $20.00 and set a “buy” rating on the stock in a research note on Friday. HC Wainwright increased their target price on Abeona Therapeutics from $15.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, April 30th. Finally, StockNews.com lowered Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to MarketBeat.com, Abeona Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $18.50.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.